Publications by authors named "Amit A Joharapurkar"

Chronic diseases associated with inflammation cause early destruction of RBCs. Complement system, part of innate immunity, is involved in such RBC destruction. Persistent inflammation causes kidney injury, leading to reduced erythropoietin release and functional iron deficiency, causing anaemia.

View Article and Find Full Text PDF
Article Synopsis
  • - Autoimmune hemolytic anemia (AIHA) is a disease caused by the body's immune system attacking red blood cells, leading to rapid hemolysis and anemia, with varying onset based on triggers.
  • - Desidustat, a medication primarily used for anemia related to chronic kidney disease, was tested in a study on mice with AIHA and showed positive results, improving levels of hemoglobin and red blood cells while reducing white blood cells and oxidative stress.
  • - The treatment with desidustat enhanced erythropoiesis (the production of red blood cells) and prevented antibody-mediated damage to red blood cells, suggesting that desidustat could be an effective option for treating AIHA.
View Article and Find Full Text PDF

Complement cascade is a defence mechanism useful for eliminating pathogenic microorganisms and damaged cells. However, activation of alternative complement system can also cause inflammation and promote kidney and retinal disease progression. Inflammation causes tissue hypoxia, which induces hypoxia-inducible factor (HIF) and HIF helps the body to adapt to inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • Many patients with chronic kidney disease experience anemia that is resistant to erythropoietin (EPO) due to factors like inflammation and improper iron usage.
  • The study tested desidustat, a drug that inhibits certain enzymes, in rats to see if it could help manage anemia in cases where EPO was ineffective.
  • Results showed that desidustat reduced resistance to EPO, lowered inflammation markers, and maintained healthy hemoglobin levels, suggesting it could be a new treatment option for EPO-resistant renal anemia.
View Article and Find Full Text PDF
Article Synopsis
  • Chronic kidney disease (CKD) leads to inflammation in the body, and desidustat is a medicine that might help treat anemia related to CKD.
  • In experiments with rats and mice that had kidney problems, desidustat showed positive effects by lowering harmful substances in the blood and helping with anemia.
  • The treatment also reduced inflammation and damage in the kidneys, suggesting it could be beneficial for people with CKD.
View Article and Find Full Text PDF

Background: Balanced coagonists of glucagon-like peptide-1 (GLP-1) and glucagon receptors are emerging therapies for the treatment of obesity and diabetes. Such coagonists also regulate lipid metabolism, independent of their body weight lowering effects. Many actions of the coagonists are partly mediated by fibroblast growth factor 21 (FGF21) signaling, with the major exception of bile homeostasis.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effects of a coagonist targeting GLP-1 and glucagon receptors on kidney problems caused by diabetes and obesity in mouse models.
  • Researchers used different groups of mice fed a high-fat diet or treated with a diabetes-inducing agent to assess changes in kidney function and overall health after 12 to 40 weeks of coagonist treatment.
  • Results showed significant improvements in kidney health, weight loss, and reduced inflammation and fibrosis, indicating that this treatment could mitigate kidney dysfunction linked to diabetes and obesity.
View Article and Find Full Text PDF
Article Synopsis
  • * Hypoxia triggers the production of hypoxia-inducible factor (HIF), which increases erythropoietin (EPO) levels and helps stimulate red blood cell formation.
  • * Prolyl hydroxylase domain (PHD) inhibitors, which stabilize HIF and lower hepcidin levels (regulating iron), are being tested in clinical trials as a new oral treatment for anemia linked to chronic diseases, with several compounds such as roxadustat and vadadustat in advanced trial phases.
View Article and Find Full Text PDF

Background And Purpose: Dipeptidyl peptidase (DPP)-4 inhibitors increase levels of glucagon-like peptide-1 (GLP-1) and provide clinical benefit in the treatment of type 2 diabetes mellitus. As longer acting inhibitors have therapeutic advantages, we developed a novel DPP-4 inhibitor, ZY15557, that has a sustained action and long half-life.

Experimental Approach: We studied the potency, selectivity, efficacy and duration of action of ZY15557, in vitro, with assays of DPP-4 activity.

View Article and Find Full Text PDF

ZYDPLA1 is a long acting enzyme dipeptidyl peptidase-4 (DPP-4) inhibitor. The comparative effect of DPP-4 inhibition after intravenous (IV) and oral administration of ZYDPLA1 in a rat model was evaluated to answer the question of route dependency and/or the need of high plasma levels of ZYDPLA1. The study was conducted using parallel design in male Wistar rats for IV/oral route (n=9 and 6, for IV and oral respectively).

View Article and Find Full Text PDF
Article Synopsis
  • ZYAN1, a prolyl hydroxylase inhibitor, is being researched for treating anemia caused by chronic kidney disease (CKD), with studies conducted on its pharmacokinetics in rat models experiencing kidney impairment.
  • In the experiment, acute kidney injury was induced using cisplatin, while chronic kidney injury was induced through nephrectomy, and the effects on ZYAN1 were evaluated by measuring its levels in blood and urine after a single oral dose.
  • Results showed that peak concentration and overall exposure of ZYAN1 were largely unaffected in mild kidney injury cases, but a significant increase in drug exposure occurred in severely impaired rats, suggesting that CKD patients might experience minimal changes in ZYAN1 processing.
View Article and Find Full Text PDF

Glucagon-like peptide-1 (GLP-1) receptor agonists modulate lipid metabolism, apart from controlling glucose homeostasis. We investigated the role of central GLP-1 receptor (GLP-1R) agonism in regulation of hepatic lipid metabolism in cholesterol-fed hamsters. Cholesterol-fed hamsters were treated by intracerebroventricular (i.

View Article and Find Full Text PDF

Type 2 diabetes is associated with increased fracture risk and delayed fracture healing; the underlying mechanism, however, remains poorly understood. We systematically investigated skeletal pathology in leptin receptor-deficient diabetic mice on a C57BLKS background (db). Compared with wild type (wt), db mice displayed reduced peak bone mass and age-related trabecular and cortical bone loss.

View Article and Find Full Text PDF

At present, inhibitors of α/β-hydrolase domain 6 (ABHD6) are viewed as a promising approach to treat inflammation and metabolic disorders. This article describes the development of 1,2,5-thiadiazole carbamates as ABHD6 inhibitors. Altogether, 34 compounds were synthesized, and their inhibitory activity was tested using lysates of HEK293 cells transiently expressing human ABHD6 (hABHD6).

View Article and Find Full Text PDF

Cannabinoid 1 (CB1) receptor antagonists reduce body weight and improve insulin sensitivity. Preclinical data indicates that an acute dose of CB1 antagonist rimonabant causes an increase in blood glucose. A stable analog of glucagon-like peptide 1 (GLP-1), exendin-4 improves glucose-stimulated insulin secretion in pancreas, and reduces appetite through activation of GLP-1 receptors in the central nervous system and liver.

View Article and Find Full Text PDF

Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors reduces body weight without inducing hyperglycemia. In addition, coagonists have demonstrated lipid lowering property, which was independent of their anorectic effect. Similarly, GLP-1 modulates cardiovascular function which is favorable for treatment of myocardial injury, cardiac dysfunction, cardiac arrhythmias, endothelial dysfunction, and blood pressure, while glucagon has a positive impact on heart rate, cardiac output, ventricular contraction and enhances cardiac performance in animals and humans.

View Article and Find Full Text PDF

Objective: Dipeptidyl peptidase-4 (DPP-4) is responsible for degradation of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), the endogenous incretins that stimulate glucose-dependent insulin secretion. The objective was to evaluate preclinical profile of a novel DPP-4 inhibitor ZYDPLA1.

Methods: In vitro inhibition potency and selectivity were assessed using recombinant enzymes and/or plasma.

View Article and Find Full Text PDF

Glucagon-like peptide-1 (GLP-1), is a hormone secreted by small intestine. Consumption of food or glucose stimulates synthesis and secretion of GLP-1 in the bloodstream, which in turn stimulates insulin secretion from pancreas and delays gastric emptying. Owing to the favorable spectrum of effects on reduction of hyperglycemia and body weight, GLP-1 mimetics are intensely pursued as therapies for the treatment of type 2 diabetes (T2DM).

View Article and Find Full Text PDF

Adiponectin is an adipocytokine that signals through plasma membrane-bound adiponectin receptors 1 and 2 (AdipoR1 and -2). Plasma adiponectin depletion is associated with type 2 diabetes, obesity, and cardiovascular diseases. Adiponectin therapy, however, is yet unavailable owing to its large size, complex multimerization, and functional differences of the multimers.

View Article and Find Full Text PDF

Worldwide prevalence of obesity has nearly doubled since 1980. Obesity is the result of interactions among the environmental factors, genetic predisposition, and human behavior. Even modest weight reduction in obese patients provides beneficial health outcomes.

View Article and Find Full Text PDF

The ethanolic extract of roots of Hemidesmus indicus R.Br. (family: Asclepiadaceae) was investigated for possible antinociceptive effect in mice.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: